Compare Biogen Inc (BIIB) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs MobilEye Global Inc — how do they compare? Biogen Inc trades at $191.88 (market cap $28.34B), while MobilEye Global Inc trades at $10.14 (market cap $8.50B). The key difference: Biogen Inc is far larger — about 3.3× MobilEye Global Inc's market cap, and Biogen Inc is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | MBLY | |
|---|---|---|
Market Cap | $28.34B | $8.50B |
Sector | Health | Technology |
52-Week High | $216.63 | $16.27 |
52-Week Low | $122.68 | $6.56 |
Enterprise Value | $30.62B | $7.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
MBLY trades at $9.75, up 2.09% today, with a bullish technical signal and strong analyst support (57.69% buy ratings). The company reported Q1 2026 EPS of $0.12, beating expectations, but faces profitability challenges with a net income margin of -203.97% for 2026. Recent news highlights its strategic shift to launch a vertically integrated U.S. robotaxi service in 2027, positioning it beyond traditional ADAS supply.
The outlook hinges on MBLY's execution of its robotaxi initiative, offering growth potential but carrying significant execution and competitive risks. While near-term fundamentals show losses, the stock's current price near the consensus target of $10.50 suggests limited upside unless profitability improves or new ventures accelerate. Investors should weigh the high-risk, high-reward profile amid volatile earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
